Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Developing a Novel Enzalutamide-Resistant Prostate Cancer Model via AR F877L Mutation in LNCaP Cells.

Current protocols - 1 Apr 2024

Wang Ruifeng, Ma Shuhua, Xu Nengwei, Gan Yumiao, Li Pengya, Zhang Jingying, Zhang Zhixiang, Gu Qingyang, Xiang Jian

Abstract excerpt

Prostate cancer is a leading diagnosis and major cause of cancer-related deaths in men worldwide. As a typical hormone-responsive disease, prostate cancer is commonly managed with androgen deprivation therapy (ADT) to curb its progression and potential metastasis. Unfortunately, progression to castration-resistant prostate cancer (CRPC), a notably more aggressive phase of the disease, occurs within a timeframe of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Benzamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Drug Resistance, Neoplasm

Share to Nitriles

Share to Prostatic Neoplasms, Castration-Resistant

Share to Receptors, Androgen

Source

Identifiers

PMID: 38652202
DOI: 10.1002/cpz1.1033

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Developing a Novel Enzalutamide-Resistant Prostate Cancer Model via AR F877L Mutation in LNCaP Cells.PMID 38652202Read ↗

A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509Semantic proximity Read ↗

Inhibition of Galectin-1 and androgen receptor axis enhances enzalutamide treatment in enzalutamide resistant prostate cancerSemantic proximity Read ↗

ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.Semantic proximity Read ↗

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).Semantic proximity Read ↗

Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamideSemantic proximity Read ↗

Identification of genes required for enzalutamide resistance in castration-resistant prostate cancer cells <i>in vitro</i>Semantic proximity Read ↗

Investigation of the Effects of Galectin-1 on Enzalutamide Sensitivity and Cellular Functions in Prostate Cancer Cells and Its Clinical Diagnostic ValueSemantic proximity Read ↗

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).Semantic proximity Read ↗

Understanding the development of enzalutamide resistance based on a functional single-cell approachSemantic proximity Read ↗

Targeting mRNA-coding genes in prostate cancer using CRISPR/Cas9 technology with a special focus on androgen receptor signalingSemantic proximity Read ↗

PHENOTYPIC CHARACTERIZATION OF TWO NOVEL CELL LINE MODELS OF CASTRATION RESISTANT PROSTATE CANCERSemantic proximity Read ↗

Novel hormone therapies for advanced prostate cancer: Understanding and countering drug resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.